The Institute of Pharmaceutical Innovation

About

Jump to About Navigation

Focus on China

In 2005 IPI senior management made the strategic decision to expand its activities into China. The rationale was simple: China is one of the fastest growing, yet in research terms least well served pharmaceutical markets in the world. China has enjoyed >20% growth for three consecutive years, and by 2009 is estimated to become the 7th largest in the world (IMS). The Chinese market is characterised by companies seeking to find ways of overcoming regulatory barriers to promoting Traditional Chinese Medicines (TCM) in global markets, generic companies looking to differentiate their products, as well as increasingly companies seeking to develop new chemical entities into global products.

Areas where the IPI is providing support in this market include:

  • Science exchange through collaborative research, PhD programmes e.g. Therapeutic Nanoparticles; In-silico Formulation; Quality by Design
  • Providing advice to Chinese companies on regulatory compliance, formulation design, manufacturing optimisation
  • Business development partnerships, where possible using scientists and facilities in China
  • Helping Chinese companies and entrepreneurs to exploit novel technology in global healthcare markets
  • Strategic research partnerships
  • Licensing and commercialisation of technology into Chinese markets
  • New joint venture companies

    The IPI is proud to have recently signed a Memorandum of Understanding with Nankai University, Tianjin, China. The aim of this collaboration agreement is for both parties to co-operate in scientific research and play an important role in advancing pharmaceutical research within China and globally.

    Current research and commercial collaborations in China include the following:

  • Partnership with Chinese National Academy of Nanotechnology and Engineering
  • Membership of Traditional Chinese Medicine (TCM) research team, funded by Ministry of Science & Technology of China (partnership between IPI, Zhejiang Chinese Medicine University, Shanghai Institute of Material Medica, Jilin University).
  • Member of Cambridge based XiangCam TCM research Centre. Other research collaborators include: Tsinghua University (China), Cambridge University, London School of Pharmacy, XiangXue Pharmaceuticals (China), Brunel University, Royal Botanic Gardens Kew, Guy’s and St Thomas’s Medical Toxicology Unit (NHS), and the IPI

    Recent press release news relating to the launch of the XiangCam TCM Research Institute.
    Press_release_1.pdf
    Press_release_2.pdf

  • Member of Consortium for Globalization of Chinese Medicine (CGCM), supported by the Universities of Cambridge, Oxford, Brunel, Nottingham and IPI
  • Ongoing contract research activities with Chinese pharmaceutical companies and contract research organisations
  • Member of the China-UK Joint Economic and Trade Commission Healthcare Working Group, a forum in which senior representatives from the British and Chinese governments and industry meet to identify opportunities for collaboration.

    The IPI continues to maintain its excellent relationships with the following key organisations:

  • UKTI
  • British Embassy in Beijing
  • Chinese Embassy in London
  • SFDA China Centre for Pharmaceutical International Exchange
  • Beijing Pharma and Biotech Centre
  • China National Spray Packaging Association and National Aerosol Committee
  • Suzhou Biobay
  • Yorkshire Forward China Office
    —————————————————————————
    Calendar of upcoming events

    March 2008 – Accessing China’s Biopharma Market Seminar. This seminar is supported by UK Trade & Investment, in collaboration with China-Britain Business Council.
    China_event_flier_with_UKTI_Logo1_GB.pdf

    May 2008 – Senior delegation from Beijing Municipal Science & Technology Commission together with Chinese industrial delegates to visit IPI

    July 2008 – TCM week held in London

    September 2008 – Training Programme held at the IPI “Realising the China opportunity: A practical guide to successful innovation in the Chinese healthcare industry” run by Dr. Qun Shao. Realising_China_Opportunity_Flyer.pdf
    —————————————————————————
    Please download our IPI brochure in Chinese
    Chinese_IPI_Brochure.pdf

    Please click here for IPI presentation in Chinese
    IPI_Introduction_(chinese).pdf

    For more information please contact

    Dr. Qun Shao
    China Programme Manager
    E:
    T:+44 (0)1274 236041
    M:+44 (0)7809 201298